吡非尼酮联合激素与免疫抑制剂治疗纤维化型IPAF的临床经验
该文回顾性分析北京协和医院2例纤维化型具有自身免疫特征的间质性肺炎(IPAF)成人患者,在激素联合免疫抑制剂治疗后肺内病变未能进一步吸收时加用吡非尼酮,治疗4~5个月后临床症状及肺部影像学均改善,提示联合吡非尼酮可能获益。
要点
- 纤维化型IPAF在激素联合免疫抑制剂改善有限时,可考虑加用吡非尼酮抗纤维化治疗。
- 2例患者加用吡非尼酮4~5个月后临床症状及肺部影像学均改善。
- 该证据来自2例回顾性病例,需更多研究验证。
核心结论
- 对于纤维化型IPAF患者,激素联合免疫抑制剂治疗后病情及胸部影像学改善有限时,联合吡非尼酮治疗可能获益。
研究设计与样本
- 回顾性分析北京协和医院呼吸内科接诊的2例纤维化型IPAF成人患者,并复习相关文献。
- 1例为43岁女性,1例为53岁男性,均结合临床、影像学及血清学特点确诊IPAF。
主要发现
- 2例患者给予激素联合免疫抑制剂后病情一度减轻,但继续治疗病情未进一步改善。
- 在此基础上联合吡非尼酮治疗4~5个月后,患者临床症状及肺部影像学均改善。
临床怎么用
- 纤维化型IPAF在激素联合免疫抑制剂治疗后肺内病变未能进一步吸收时,可考虑在原有治疗基础上加用吡非尼酮。
局限性
- 仅为2例患者的回顾性分析,样本量小,结论需更大样本研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the effect of pirfenidone in fibrotic interstitial pneumonia with autoimmune features (IPAF) after treatment with corticosteroids and immunosuppressants. Methods: We conducted a retrospective analysis of 2 adult patients with IPAF in the Peking Union Medical College Hospital. As their fibrotic interstitial lung disease failed to improve with further treatment with corticosteroids and immunosuppressants, they were treated with pirfenidone based on corticosteroids and immunosuppressants. Their clinical, chest radiological data and prognosis were collected and relevant literatures were reviewed. Results: One patient was a 43 year old female, the other was a 53 year old male. IPAF was diagnosed with their classic clinical, serological and radiological features. They were partially responded to corticosteroids and immunosuppressants at the initial period. Pirfenidone was suggested for them as their lung fibrosis was not improved further with immunosuppressive therapy. After 4-5 months treatment with pirfenidone, based on corticosteroids and immunosuppressant administration, their clinical and radiological manifestations improved significantly. Conclusions: Pirfenidone might be a good add-on choice for fibrotic IPAF when the disease did not respond well to corticosteroids and immunosuppressants. 目的: 探讨糖皮质激素(简称激素)联合免疫抑制剂基础上联合吡非尼酮治疗纤维化型具有自身免疫特征的间质性肺炎(IPAF)的疗效。 方法: 回顾性分析北京协和医院呼吸内科接诊的2例纤维化型IPAF的患者,在激素联合免疫抑制剂治疗后,肺内病变未能进一步吸收之际,评价联合吡非尼酮抗纤维化治疗后间质性肺炎的转归。 结果: 1例为43岁女性,1例为53岁男性,结合临床、影像学及血清学特点均确诊IPAF,给予激素联合免疫抑制剂后病情一度减轻,但继续治疗病情未进一步改善;在此基础上联合吡非尼酮治疗4~5个月后,患者临床症状及肺部影像学均改善。 结论: 对于纤维化型IPAF患者,在积极地给予激素联合免疫抑制剂治疗后,病情及胸部影像学方面改善有限的情况下,联合吡非尼酮治疗可能获益。.
引用
- Huang H, Sun YX, Li S, et al. [The clinical experience of pirfenidone based on corticosteroids and immunosuppressant treatment for interstitial pneumonia with autoimmune features]. Zhonghua Jie He He Hu Xi Za Zhi. 2019. PMID: 31484245. doi:10.3760/cma.j.issn.1001-0939.2019.09.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。